Chicago Equity Partners’s NovoCure NVCR Stock Holding History

Chicago Equity Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$589K	Sell	8,747 -32,555	-79%	-$2.57M	0.06%	391
2019 Q4	$3.48M	Sell	41,302 -31,953	-44%	-$2.58M	0.2%	144
2019 Q3	$5.48M	Buy	73,255 +22,330	+44%	+$1.79M	0.26%	98
2019 Q2	$3.22M	Buy	50,925 +6,435	+14%	+$326K	0.14%	195
2019 Q1	$2.14M	Buy	+44,490	New	+$2.14M	0.08%	328
2018 Q4	–	Sell	-162,620	Closed	-$8.52M	–	855
2018 Q3	$8.52M	Sell	162,620 -50,255	-24%	-$2M	0.25%	106
2018 Q2	$6.66M	Buy	212,875 +66,650	+46%	+$1.85M	0.2%	139
2018 Q1	$3.19M	Sell	146,225 -9,500	-6%	-$204K	0.1%	279
2017 Q4	$3.15M	Buy	155,725 +53,930	+53%	+$1.04M	0.1%	274
2017 Q3	$2.02M	Buy	101,795 +37,110	+57%	+$729K	0.06%	369
2017 Q2	$1.12M	Buy	+64,685	New	+$835K	0.03%	483

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Chicago Equity Partners's NVCR Position: Q1 2020 in Review

Chicago Equity Partners reduced its NovoCure (NVCR) stake by 79% in Q1 2020, selling an estimated $2.57M and leaving 8,747 shares worth $589K. The position accounts for 0.06% of the portfolio, ranked #391.

Chicago Equity Partners first reported a position in NVCR in Q2 2017 and has held it in 11 quarters since. The position peaked at $8.52M in Q3 2018. 271 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

Chicago Equity Partners held 8,747 shares of NovoCure worth $589K as of Q1 2020.
Chicago Equity Partners sold 32,555 NovoCure shares in Q1 2020, an estimated $2.57M.
NovoCure made up 0.06% of Chicago Equity Partners's portfolio in Q1 2020, its #391 holding.
Chicago Equity Partners first reported a position in NovoCure in Q2 2017 and has held it in 11 quarters since.
Chicago Equity Partners's NovoCure position peaked at $8.52M in Q3 2018.
271 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.